NHLBI state of the science symposium in therapeutic apheresis: Knowledge gaps and research opportunities in the area of hematology-oncology.
The National Heart Lung and Blood Institute (NHLBI) hosted a two-day state of the science symposium on therapeutic apheresis in Bethesda, MD on November 28th-29th, 2012. The purpose of the symposium was multifaceted, and included the following aims: (a) To discuss this state of research and key scientific questions in apheresis medicine; (b) To identify gaps in knowledge for relevant cardiovascular diseases, hematological and oncological diseases, infectious diseases and sepsis, renal diseases, and neurological diseases where there may be strong therapeutic rationale for the application of apheresis treatments; (c) To explore ways of coordinating therapeutic apheresis with other medical disciplines and treatment modalities; (d) To identify and prioritize the most important research questions to be answered in apheresis medicine; and (e) To offer NHLBI suggestions on how a structured research approach can be applied to the therapeutic apheresis research agenda in future years. The following document summarizes three such key proposals presented at the meeting for evaluating apheresis therapy for the treatment of pain in sickle cell disease, heparin induced thrombocytopenia, and leukostasis from acute myeloid leukemia. The challenges and limitations regarding apheresis therapy for each disease are discussed, and avenues for future investigation for each disease are outlined.
Medical Sciences Institute, BloodCenter of Wisconsin, Milwaukee, Wisconsin.|Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Matthew S
MS
Karafin
New York Blood Center, New York.|Department of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Bruce S
BS
Sachais
Seattle Cancer Care Alliance and Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
Laura
L
Connelly-Smith
Medical Sciences Institute, BloodCenter of Wisconsin, Milwaukee, Wisconsin.|Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Joshua J
JJ
Field
Seattle Cancer Care Alliance and Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
Michael L
ML
Linenberger
Medical Sciences Institute, BloodCenter of Wisconsin, Milwaukee, Wisconsin.|Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Anand
A
Padmanabhan
D000755:Anemia, Sickle Cell / Q000628:therapy; D001323:Autoantibodies / Q000097:blood / Q000302:isolation & purification; D001781:Blood Component Removal / Q000639:trends; D006405:Hematology / Q000639:trends; D006493:Heparin / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008495:Medical Oncology / Q000639:trends; D054555:National Heart, Lung, and Blood Institute (U.S.); D010978:Platelet Factor 4 / Q000276:immunology; D014481:United States
D001323:Autoantibodies; D010978:Platelet Factor 4; D006493:Heparin
NHLBI symposium; acute myeloid leukemia (AML); apheresis research; heparin induced thrombocytopenia (HIT); sickle cell disease